NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 14 March 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Alex Cale Items 1 to 5.2.2
4. Michael Chambers Present for all items
5. Dr Mark Corbett Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Present for all items
9. Dr Pedro Saramago Goncalves Present for all items
10. John Hampson Present for all items
11. Dr Steven Lloyd Items 1 to 5.2.2
12. Iain McGowan Present for all items
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Dr Clare Offer Present for all items
16. Dr Kate Ren Present for all items
17. Professor Andrew Renehan Present for all items
18. Dr Arpit Srivastava Present for all items
19. Professor Matthew Stevenson Present for all items
20. Dr Britta Stordal Items 1 to 5.2.2
21. Professor Paul Tappenden Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Christian Griffiths, Heath Technology Assessment Adviser Items 5 to 5.2.2

Anuja Chatterjee, Heath Technology Assessment Analyst Items 1 to 4.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 1 to 4.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 5 to 5.2.2

Benjamin Gregory, Business Analyst, Resource Impact Items 5 to 5.2.2

Emilene Coventry, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 5 to 5.2.2

Heidi Livingstone, Public Involvement Adviser Items 1 to 4.1.3

Lyn Davies, Coordinator, Corporate Office Items 1 to 4.1.3

Emma Gordon, Coordinator, Corporate Office Items 5 to 5.1.3

Gemma Smith, Coordinator, Committee Operations Present for all items

Iain Cannell, Administrator, Technology Appraisals Present for all items

NICE staff (observers) present

Nigel Gumbleton, Health Technology Assessment Analyst Items 1 to 4.2.2

Milena Wobbe, Technical Analyst, Managed Access Items 1 to 4.2.2

Abigail Stephens, Project Manager, Topic Selection Items 1 to 4.2.2

Stephen Duffield, Senior Analyst, Methods and Standards Items 5 to 5.2.2

Sarah Wilkes, Technical Analyst, Commercial Liaison Items 5 to 5.2.2

Catrin Austin, Technical Analyst, Methods & Economics Items 5 to 5.2.2

Stephen Norton, Technical Analyst, Managed Access Items 5 to 5.2.2

Giacomo De Guisa, Technical Analyst, Guideline development Items 5 to 5.2.2

Georgina Fletcher, Media relations executive Items 5 to 5.2.2

External assessment group representatives present

Graham Scotland, Aberdeen HTA Group Items 1 to 4.1.3

Dolapo Ayansina, Aberdeen HTA Group Items 1 to 4.1.3

Dan Gallacher, Warwick Evidence Items 5 to 5.1.3

Mandy Maredza, Warwick Evidence Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 5.2.1

Professor Nagesh Kalakonda, Professor and Honorary Consultant, Haemato-oncology, clinical expert nominated by Janssen-Cilag Ltd, Items 1 to 4.1.3

Dr Nicolas Martinez-Calle, Consultant Haematologist, clinical expert nominated by the UK CLL Forum and British Society of Haematology, Items 1 to 4.1.3

Nick York, Patient Advocacy Healthcare Liaison Officer, patient expert nominated by Leukaemia Care, Items 1 to 4.1.3

Steve Abrahams, Patient expert nominated by the CLL Support Association, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Iftab Akram. Dr Nigel Langford and Dr Rob Forsyth.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 14 February 2023.

### Appraisal of Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID3860]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Janssen-Cilag Ltd.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has co-ordinated a training programme for Roche in Real World Evidence, which did not consider any Roche products, he has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has provided advice to Sanofi in an unrelated disease area (COPD). It was agreed that his declarations would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Novartis and Roche in an unrelated disease (MS). It was agreed that his declarations would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Committee member Professor Matt Stevenson declared financial interests as he has undertaken work for Astra Zeneca Rare Diseases in Myasthenia Gravis. It was agreed that his declarations would not prevent Professor Stevenson from participating in discussions on this appraisal.
* Committee member Dr Steven Lloyd declared financial interests as he has provided educational advice on respiratory pathways and vaccinations for Pfizer UK , Roche and Viatris and was paid for items of education. It was agreed that his declarations would not prevent Dr Lloyd from participating in discussions on this appraisal.
* Nominated clinical expert Professor Nagesh Kalakonda declared direct financial interest as he has received speaker fees from Janssen for participation in an educational event focused on ibrutinib and CLL. It was agreed that his declaration would not prevent Professor Kalakonda from providing expert advice to the committee.
* Nominated clinical expert Dr Nicolas Martinez-Calle declared direct financial interests as he has received travel support from Takeda, Abbvie and AstraZeneca, honoraria from AbbVie, Janssen, AstraZeneca and Roche, a research grant from Celgene in 2015 and has taken part on advisory boards for Takeda, Abbvie and Beigene. It was agreed that his declaration would not prevent Dr Martinez-Calle from providing expert advice to the committee.
* Nominated patient expert Nick York declared indirect financial interests as Leukaemia Care has received funding and honorarium from Janssen and AbbVie, honorarium from AstraZeneca UK, emergency funding from Gilead Sciences and funding from Pfizer for support services. It was agreed that his declaration would not prevent Nick from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ugochi Nwulu, Dr Pedro Saramago Goncalves and John Hampson.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10746>

### Appraisal of Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the NHSE expert, external assessment group representatives, members of the public and company representatives from Roche.
		2. The chair asked all committee members and NHSE expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Roche in an unrelated disease area (MS).). It was agreed that his declarations would not prevent Dr Richard Nicholas from participating in discussions on this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10816>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on 12 April 2023